Summary
Oxaliplatin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Breast Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Breast Cancer. ClinicalTrials.gov lists 8 registered trials linking Oxaliplatin to Breast Cancer: 1 is active or not yet recruiting; 2 have completed; 5 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT00674206). The largest enrolment is 358 participants (NCT07464769). Registration activity spans 2008 to 2026. The literature layer holds 14 publications for this pair: 2 Cochrane reviews, 2 meta-analyses, 2 systematic reviews, 3 randomised controlled trial publications and 5 clinical trial publications. Publication years run from 2006 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Breast Cancer ranks 1462 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous regression documented but rare (<0.5%); 5-year survival stage I: ~99%; stage IV: ~28% overall, improving with modern therapy.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 63.0 (trials 13.0, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 1 active / not yet recruiting, 2 completed, 5 other |
| Linked publications | 14 (5 clinical trial publications, 3 randomised controlled trial publications, 2 Cochrane reviews, 2 meta-analyses, 2 systematic reviews) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | BRCA1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00674206 | A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer 2008 | terminated | Phase 2 | 6 |
| NCT01937507 | Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer 2012 | terminated | Phase 2 | 2 |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors 2023 | terminated | Phase 1 | 31 |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors 2010 | terminated | Phase 1 | 16 |
| NCT02077998 | Oxaliplatin in Treating Patients With Metastatic Breast Cancer 2015 | completed | Early Phase 1 | 1 |
| NCT03838406 | BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer 2017 | completed | Not applicable | 30 |
| NCT07464769 | Compression Therapy of Hands and Feet for the Prevention of Taxane- or Oxaliplatin-induced Peripheral Neuropathy 2026 | not yet recruiting | Not applicable | 358 |
| NCT03009058 | Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer 2017 | terminated | PHASE1, PHASE2 | 2 |
Published literature
- Clinical trial publication Efficacy and safety of trastuzumab biosimilar CT-P6 plus SOX or CapeOX in HER2-positive advanced gastric cancer: a multicenter phase II KSCC-TROX studyOki E, Yamada T, Kashiwada T et al. · Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026 · PMID 41870735
- Meta-analysis Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid TumorsHe Y, Gao C, Zhang S et al. · Cancer medicine · 2026 · PMID 42043855
- Clinical trial publication Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial MalignanciesJaeger-Ruckstuhl CA, Specht JM, Voutsinas JM et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · 2025 · PMID 39466024
- Systematic review Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver MalignancyKennedy AS, Brown DB, Fakih M et al. · Journal of vascular and interventional radiology : JVIR · 2024 · PMID 38885899
- Clinical trial publication Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)Misawa S, Denda T, Kodama S et al. · BMC cancer · 2023 · PMID 37951905
- Clinical trial publication An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal CancerAntoniotti C, Boccaccino A, Seitz R et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · 2023 · PMID 37022350
- Clinical trial publication A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)Lee DW, Keam B, Lee KS et al. · Cancer research and treatment · 2023 · PMID 36397238
- Systematic review Combination Chemotherapy with Selected Polyphenols in Preclinical and Clinical Studies-An Update OverviewJakobušić Brala C, Karković Marković A, Kugić A et al. · Molecules (Basel, Switzerland) · 2023 · PMID 37175156
- Randomized controlled trial A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathyLopez G, Eng C, Overman M et al. · Scientific reports · 2022 · PMID 36348045
- Randomized controlled trial Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathyBeijers AJM, Bonhof CS, Mols F et al. · Annals of oncology : official journal of the European Society for Medical Oncology · 2020 · PMID 31912787
- Randomized controlled trial EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer groupWagner AD, Grabsch HI, Mauer M et al. · BMC cancer · 2019 · PMID 31126258
- Cochrane review Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trialsIacovelli R, Pietrantonio F, Palazzo A et al. · British journal of clinical pharmacology · 2014 · PMID 24962653
- Cochrane review KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic AnalysisMedical Advisory Secretariat · Ontario health technology assessment series · 2010 · PMID 23074403
- Meta-analysis Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancersAjani J · Cancer · 2006 · PMID 16770784
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Oxaliplatin approved for Breast Cancer?
Oxaliplatin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Breast Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Breast Cancer. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Oxaliplatin in clinical trials for Breast Cancer?
ClinicalTrials.gov lists 8 registered trials linking Oxaliplatin to Breast Cancer: 1 is active or not yet recruiting; 2 have completed; 5 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT00674206). The largest enrolment is 358 participants (NCT07464769). Registration activity spans 2008 to 2026.
What does the evidence show for Oxaliplatin in Breast Cancer?
Oxaliplatin has both completed registered trials and synthesis-level publications linked to Breast Cancer. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.